1-20 of 245 results for subject:Screening
Librarians' tools
- Search time
- 0.231 seconds
- Solr query time
- 0.008 seconds
- Search query
- subject:Screening
- We searched for
- subject_t:Screening OR subject_ses:92923
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
Legislative stage
Legislation
Subject
More
Publisher
That this House recognises the life-changing difference early diagnosis and treatment can make for babies with spinal muscular atrophy (SMA); notes that SMA is a rare but serious genetic condition which, if untreated, can cause severe disability or early death; further notes that gene therapies exist which are most effective when given before symptoms appear; acknowledges that SMA is not currently included in the routine newborn bloodspot screening programme (formerly known as heel prick test) in England, Wales or Northern Ireland; also notes that a two-year pilot will begin in Scotland in spring this year and that the National Screening Committee is currently reviewing whether to introduce screening across the UK; and therefore calls on the Government to act urgently with the NHS, devolved health authorities, and the National Screening Committee to introduce SMA screening for all newborns across the UK.
That this House recognises the life-changing difference early diagnosis and treatment can make for babies with spinal muscular atrophy (SMA); notes that SMA is a rare but serious genetic condition which, if untreated, can cause severe disability or early death; further notes that gene therapies exist which are most effective...
To ask the Secretary of State for Health and Social Care, if he will issue guidance on health screening for people who have had a family member die from sudden cardiac death under the age of 35.
To ask the Secretary of State for Health and Social Care, if he will issue guidance on health screening for people who have had a family member die from sudden cardiac death under the age of 35.
NHS England has published the national service specification Inherited Cardiac Conditions (All Ages), which covers patients who often present as young adults with previously undiagnosed cardiac disease and families requiring follow up due to a death from this cause. This describes the service model and mandated guidelines and guidance that should be followed to support the diagnosis and treatment of patients or family members. It also includes the requirement for inherited cardiac conditions services to investigate suspected cases. Further information on the Inherited Cardiac Conditions (All Ages) service specification is available at the following link:
https://www.england.nhs.uk/wp-content/uploads/2017/11/cardiology-inherited-cardiac-conditions.pdf
Genomic testing in the National Health Service in England is provided through the NHS Genomic Medicine Service and is delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory (the Test Directory), which includes tests for over 7000 rare diseases with an associated genetic cause and over 200 cancer clinical indications, including both whole genome sequencing (WGS) and non-WGS testing. Further information on the Test Directory is available at the following link:
https://www.england.nhs.uk/publication/national-genomic-test-directories/
A robust and evidence-based process and policy is in place to routinely review the Test Directory to ensure that genomic testing continues to be available for all patients for whom it would be of clinical benefit, while delivering value for money for the NHS. Further information on this process is available at the following link:
https://www.england.nhs.uk/genomics/the-national-genomic-test-directory/
Genomics has an important role to play in diagnosing and supporting the treatment and management of a number of cardiac conditions. The Test Directory sets out the eligibility criteria for patients to access testing, as well as the genomic targets to be tested and the method that should be used, and this includes genomic testing for a number of conditions which affect the heart, such as testing for familial hypercholesteremia, cardiomyopathies, Long QT syndrome, Brugada syndrome, and others.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of (a) specialist bereavement support and (b) familial screening services for the family members of a person who died from a cardiac condition under the age of 35.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of (a) specialist bereavement support and (b) familial screening services for the family members of a person who died from a cardiac condition under the age of 35.
NHS England has published the national service specification Inherited Cardiac Conditions (All Ages), which covers patients who often present as young adults with previously undiagnosed cardiac disease and families requiring follow up due to a death from this cause. This describes the service model and mandated guidelines and guidance that should be followed to support the diagnosis and treatment of patients or family members. It also includes the requirement for inherited cardiac conditions services to investigate suspected cases. Further information on the Inherited Cardiac Conditions (All Ages) service specification is available at the following link:
https://www.england.nhs.uk/wp-content/uploads/2017/11/cardiology-inherited-cardiac-conditions.pdf
Genomic testing in the National Health Service in England is provided through the NHS Genomic Medicine Service and is delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory (the Test Directory), which includes tests for over 7000 rare diseases with an associated genetic cause and over 200 cancer clinical indications, including both whole genome sequencing (WGS) and non-WGS testing. Further information on the Test Directory is available at the following link:
https://www.england.nhs.uk/publication/national-genomic-test-directories/
A robust and evidence-based process and policy is in place to routinely review the Test Directory to ensure that genomic testing continues to be available for all patients for whom it would be of clinical benefit, while delivering value for money for the NHS. Further information on this process is available at the following link:
https://www.england.nhs.uk/genomics/the-national-genomic-test-directory/
Genomics has an important role to play in diagnosing and supporting the treatment and management of a number of cardiac conditions. The Test Directory sets out the eligibility criteria for patients to access testing, as well as the genomic targets to be tested and the method that should be used, and this includes genomic testing for a number of conditions which affect the heart, such as testing for familial hypercholesteremia, cardiomyopathies, Long QT syndrome, Brugada syndrome, and others.
To ask the Secretary of State for Culture, Media and Sport, if she will (a) have discussions with Cabinet colleagues and (b) make it her policy to implement mandatory health screenings for people engaged in (a) professional and (b) semi-professional sports.
To ask the Secretary of State for Culture, Media and Sport, if she will (a) have discussions with Cabinet colleagues and (b) make it her policy to implement mandatory health screenings for people engaged in (a) professional and (b) semi-professional sports.
The safety, wellbeing and welfare of everyone taking part in sport is absolutely paramount.
National Governing Bodies (NGBs) and professional sports leagues where applicable are responsible for ensuring that appropriate measures are in place to protect participants from harm. NGBs and sports leagues are independent of Government, but the Government expects them to make the health and safety of players their top priority.
The Government will continue to discuss athlete safety with sports and other stakeholders to ensure that everyone can take part in sport as safely as possible.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of offering prostate cancer screening to men considered to be at high risk on (a) NHS costs and (b) health outcomes.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of offering prostate cancer screening to men considered to be at high risk on (a) NHS costs and (b) health outcomes.
The Department is guided on screening policy by the UK National Screening Committee. The committee has commissioned a university to carry out a high quality review and cost effectiveness model of the evidence for a national prostate cancer screening programme. The work will include costs and health outcomes. This includes targeted approaches to high risk groups and an offer to all men defined by age. The committee expects to receive the report later this year.
To ask the Secretary of State for Health and Social Care, if he will conduct a review on the prevention of sudden cardiac death that includes (a) an estimation of the incidence of sudden cardiac death, (b) methods to (i) detect and (ii) minimise cardiac conditions and (c) recommendations for...
To ask the Secretary of State for Health and Social Care, if he will conduct a review on the prevention of sudden cardiac death that includes (a) an estimation of the incidence of sudden cardiac death, (b) methods to (i) detect and (ii) minimise cardiac conditions and (c) recommendations for...
NHS England is currently working with a range of stakeholders to review the national service specification for inherited cardiac conditions. This covers patients who often present as young adults with previously undiagnosed cardiac disease or families requiring follow up due to a death from this cause, including sudden cardiac death. The service specification can be accessed at the following link:
https://www.england.nhs.uk/wp-content/uploads/2017/11/cardiology-inherited-cardiac-conditions.pdf
Over the past five financial years, 2019/20 to 2023/24, The National Institute for Health and Care Research (NIHR) has invested £145 million in cardiovascular and stroke research directly through NIHR research programmes. The NIHR has also made other significant investments in NIHR infrastructure that collectively strengthen specialist facilities, the workforce, and support services to enable research in the health and care system. This investment has enabled significant cardiovascular disease and stroke research funded by other funders to take place.
To ask the Secretary of State for Health and Social Care, if he will take steps to increase cardiac screening for people with a familial risk of sudden cardiac death.
To ask the Secretary of State for Health and Social Care, if he will take steps to increase cardiac screening for people with a familial risk of sudden cardiac death.
The UK National Screening Committee last reviewed screening for sudden cardiac death in young people in December 2019. After carefully considering the evidence, the committee concluded that a screening programme in all young people under the age of 39 years old should not be offered in the United Kingdom. Further information is available at the following link:
https://www.gov.uk/government/news/screening-for-risk-of-sudden-cardiac-death-not-recommended
Research showed that current tests are not accurate enough to use in young people without symptoms. Incorrect test results can cause harm by giving false reassurance to individuals with the condition, which may have been missed by the screening test, whilst individuals without the condition may receive a positive test result, which can lead to unnecessary tests and treatments.
To ask the Secretary of State for Health and Social Care, when the National Screening Committee plans to publish an update to guidance on screening for sudden cardiac death in people under 39.
To ask the Secretary of State for Health and Social Care, when the National Screening Committee plans to publish an update to guidance on screening for sudden cardiac death in people under 39.
The UK National Screening Committee (UK NSC) is currently examining the evidence for this condition and will open a public consultation to seek comments from members of the public and stakeholders on this in due course. Further information, including on how to keep up to date on the work of the UK NSC, is available at the following link:
https://www.gov.uk/government/organisations/uk-national-screening-committee
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 3 December 2024 to Question 5537 on Bowel Cancer: Screening, whether he expects bowel screening for 50 year-olds to be completed by (a) autumn or (b) winter 2025.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 3 December 2024 to Question 5537 on Bowel Cancer: Screening, whether he expects bowel screening for 50 year-olds to be completed by (a) autumn or (b) winter 2025.
The National Health Service in England has been gradually reducing the age for bowel screening from 60 years old down to 50 years old, since 2021/22. The extension to 50 years old is expected to be completed by 31 March 2025.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that people over 65 can access free health checks every five years.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that people over 65 can access free health checks every five years.
The NHS Health Check programme, England’s cardiovascular disease (CVD) prevention programme, aims to prevent CVD in people aged 40 to 74 years old, and is offered every five years. During 2023/24, over 1.4 million people received an NHS Health Check, and through behavioural and clinical interventions, the programme prevents approximately 500 heart attacks and strokes a year.
To improve access and engagement with the NHS Health Check, we are developing a new digital service which will complement the existing face to face programme and enable people to undertake the NHS Health Check in the comfort of their own home.
The Department is developing policy proposals and advice to ministers on options to improve the uptake and impact of the NHS Health Check programme. The work will consider the recommendations of the recent National Audit Office’s report, Progress on CVD Prevention.
Statement on the national cancer plan.
Statement on the national cancer plan.
With permission, I wish to make a statement on the national cancer plan. Today is World Cancer Day. Almost everyone in our country has been affected by cancer, either themselves or through a friend or relative. Having lost both my parents to cancer, I am so grateful to the Prime...
With permission, I wish to make a statement on the national cancer plan. Today is World Cancer Day. Almost everyone in our country has been affected by cancer, either themselves or through a friend or relative. Having lost both my parents to cancer, I am so grateful to the Prime...
I start by genuinely thanking the shadow Minister for the co-operation she has pledged as we seek to improve the outcomes for people with cancer. This is not a party political issue. We all want people to be diagnosed more quickly and to be put on the effective treatment pathways...
I start by genuinely thanking the shadow Minister for the co-operation she has pledged as we seek to improve the outcomes for people with cancer. This is not a party political issue. We all want people to be diagnosed more quickly and to be put on the effective treatment pathways...
I am very grateful to my hon. Friend for her question. Those of us who knew Margaret miss her very much; she was such a towering figure in the Labour party for so many years, and we on the Labour Benches have a lot to thank her—and, indeed, my hon....
I am very grateful to my hon. Friend for her question. Those of us who knew Margaret miss her very much; she was such a towering figure in the Labour party for so many years, and we on the Labour Benches have a lot to thank her—and, indeed, my hon....
One reason we think a national cancer plan is so important is precisely to get the investment in the areas we need so that we can tackle those health inequalities. There are very real inequalities when it comes to the diagnosis of cancer and, more importantly, the treatment and therefore...
One reason we think a national cancer plan is so important is precisely to get the investment in the areas we need so that we can tackle those health inequalities. There are very real inequalities when it comes to the diagnosis of cancer and, more importantly, the treatment and therefore...
Absolutely. My hon. Friend raises a really important point about how people receive pain relief and how that is managed. There are some really good examples out there of how it is done really well and, shockingly, there are some that are less good. We want to learn from the...
Absolutely. My hon. Friend raises a really important point about how people receive pain relief and how that is managed. There are some really good examples out there of how it is done really well and, shockingly, there are some that are less good. We want to learn from the...
I thank the right hon. Gentleman for that suggestion and will ask my officials to look into it. I am very keen that we maximise the latest advances in technology, genomics, life sciences and research to ensure that we identify people who are at risk of cancer, preferably before they...
I thank the right hon. Gentleman for that suggestion and will ask my officials to look into it. I am very keen that we maximise the latest advances in technology, genomics, life sciences and research to ensure that we identify people who are at risk of cancer, preferably before they...
I am very grateful to my hon. Friend for all the work that she has done on ovarian cancer since becoming an MP. She knows—the rest of the House might not—that I lost my mum to ovarian cancer. I was 19 when my mum died and she was only 50—my...
I am very grateful to my hon. Friend for all the work that she has done on ovarian cancer since becoming an MP. She knows—the rest of the House might not—that I lost my mum to ovarian cancer. I was 19 when my mum died and she was only 50—my...
It absolutely is, and I thank the hon. Lady for agreeing to co-chair the re-formed taskforce. I know that she cares passionately about this issue, and it was lovely to meet Charlotte some time before Christmas.
Cancer is terrible, and cancer affecting children even more so. As the hon. Lady knows,...
It absolutely is, and I thank the hon. Lady for agreeing to co-chair the re-formed taskforce. I know that she cares passionately about this issue, and it was lovely to meet Charlotte some time before Christmas.
Cancer is terrible, and cancer affecting children even more so. As the hon. Lady knows,...
I absolutely do. That shift to analogue to digital, and the use of the latest advantages in technology, science and research, will push the boundaries of what is possible when it comes to diagnosing and treating some of the rarer cancers, on which we have made virtually zero progress in...
I absolutely do. That shift to analogue to digital, and the use of the latest advantages in technology, science and research, will push the boundaries of what is possible when it comes to diagnosing and treating some of the rarer cancers, on which we have made virtually zero progress in...